Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Planet 13 HoldingsPLNH -7.91%31 3-Year EBITDA Growth Rate is 5.80% as of Mar. 2026, which is 85% below its 10-year median of 38.10. GuruFocus rates PLNH with a GF Score™ of 31/100 and a GF Value™ of $0.29 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 813 Drug Manufacturers companies, Planet 13 Holdings ranks worse than 54.98% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 5.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 10 years, the highest 3-Year average EBITDA Per Share Growth Rate of Planet 13 Holdings was 45.00% per year. The lowest was 5.80% per year. And the median was 38.10% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Planet 13 Holdings 3-Year EBITDA Growth Rate Related Terms
PLNH vs ZTS, UTHR: 3-Year EBITDA Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Planet 13 Holdings's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Planet 13 Holdings 3-Year EBITDA Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Planet 13 Holdings's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Planet 13 Holdings's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 5.80% mean?
Planet 13 Holdings (PLNH) has a 3-Year EBITDA Growth Rate of 5.80% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Planet 13 Holdings and its competitors. This is 85% below median its historical median of 38.10. Over the past decade, Planet 13 Holdings' 3-Year EBITDA Growth Rate has ranged from 5.80 to 45.00. According to the industry distribution chart, Planet 13 Holdings ranks #447 out of 813 companies in the Drug Manufacturers industry, placing it in the top 55%.
Is Planet 13 Holdings' 3-Year EBITDA Growth Rate too high?
Planet 13 Holdings' current 3-Year EBITDA Growth Rate of 5.80% is 85% below median its 10-year median of 38.10. Over the past 10 years, this metric has ranged from a low of 5.80 to a high of 45.00. The Drug Manufacturers industry median 3-Year EBITDA Growth Rate is 8.80. Planet 13 Holdings' value of 5.80% is 34.1% below this industry median. Based on the distribution chart, Planet 13 Holdings ranks #447 out of 813 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Planet 13 Holdings has a GF Score™ of 31/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Planet 13 Holdings' 3-Year EBITDA Growth Rate compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Planet 13 Holdings ranks #447 out of 813 companies for 3-Year EBITDA Growth Rate. This places Planet 13 Holdings in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 8.80. Planet 13 Holdings' value of 5.80% is 34.1% below this benchmark. Historically, Planet 13 Holdings' own 3-Year EBITDA Growth Rate has ranged from 5.80 to 45.00 over the past decade. While the company's 10-year median is 38.10 vs. the industry median of 8.80, Planet 13 Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Drug Manufacturers company?
The median 3-Year EBITDA Growth Rate among Drug Manufacturers companies is 8.80, based on 813 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Planet 13 Holdings's current 3-Year EBITDA Growth Rate of 5.80% is 34.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Planet 13 Holdings and its competitors. For the Drug Manufacturers industry, the median 3-Year EBITDA Growth Rate is 8.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Planet 13 Holdings's current 3-Year EBITDA Growth Rate is 5.80%, which is 85% below median its own 10-year median of 38.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Planet 13 Holdings stock overvalued right now?
Based on GuruFocus' analysis, Planet 13 Holdings (PLNH) is currently considered Possible Value Trap. The stock's GF Value™ is $0.29, compared to a current price of $0.12 — trading 58.3% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 5.80%, which is 85% below median its 10-year median of 38.10 and 34.1% below the Drug Manufacturers industry median of 8.80. Planet 13 Holdings' overall GF Score™ is 31/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Planet 13 Holdings (PLNH), the current 3-Year EBITDA Growth Rate is 5.80% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Planet 13 Holdings (PLNH) Overvalued in 2026?
Based on GuruFocus' analysis, Planet 13 Holdings stock appears to be undervalued.
The current stock price of $0.12 is trading 58.3% below its estimated GF Value™ of $0.29.
GuruFocus considers Planet 13 Holdings to be Possible Value Trap.
Key valuation signals for PLNH:
3-Year EBITDA Growth Rate: 5.80% (85% below median its 10-year median of 38.10)
GF Value™: $0.29 vs. price of $0.12 (58.3% below fair value)
Industry Position: 34.1% below the Drug Manufacturers median (#447 of 813)
No single metric tells the full story. See the PLNH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Planet 13 Holdings Inc a vertically integrated cultivator and provider of cannabis and cannabis-infused products in the States of Nevada and California, with retail cannabis operations in Illinois. The company owns and manufactures cannabis products under the following brands: HaHa (gummies and beverages), Dreamland (chocolates), TRENDI (vapes and concentrates), Medizin (flower, vapes, concentrates), Leaf and Vine (vapes).
31GF Score
Get the complete analysis for PLNH
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PLNH has been successfully added to your 
